

RESPONSE TO REVIEWERS AND EDITORS

Jun 22, 2021

Lian-Sheng Ma,
Science Editor, Company Editor-in-Chief, Editorial Office
World Journal of Gastroenterology

Re: Manuscript No.: 66701, Retrospective Study

Dear Editors:

We wish to re-submit our manuscript, which is now titled **“Prolonged survival in patients with hand-foot skin reaction secondary to cooperative sorafenib treatment.”**

We wish to express our appreciation to the reviewer for his/her insightful comments, which helped us improve our paper significantly. We carefully reviewed these comments and revised the manuscript accordingly. Our response to Reviewer 1’s comment is included below, and the corresponding changes in the manuscript are highlighted in yellow. Additionally, we made changes in the manuscript based on the comments from the Editorial Office; these changes are also highlighted in yellow.

We hope the revised version is now suitable for publication and look forward to hearing from you in due course.

Sincerely,

Masanori Ochi, MD

Department of Gastroenterology, Hitachi General Hospital, Ibaraki 317-0077, Japan

Email: maochi-tei@umin.ac.jp

Telephone: +81-294-231111

Fax: +81-294-238351

Reviewer 1's comments: *In this manuscript, the authors developed a mutual cooperation system and found this system can increase treatment duration and improve prognosis in patients with HFSR. In addition, the mutual cooperation system could be applied to the management of treatment with other multi-kinase inhibitors, which can prolong the overall survival of patients. In general, the research is novel. However, there are still several points should revise as follows: 1.The authors should perform the univariate analysis and multivariate analysis of BCLC staging B. 2.The authors should supply the Kaplan-Meier survival analysis of patients with stage B and C respectively.*

Response: Thank you for these constructive suggestions. The results of our univariate and multivariate analyses of BCLC stage B are now present in Table 6. In addition, we added a figure showing the Kaplan-Meier survival analysis results for patients with BCLC stages B and C (Figure 2).